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 Abstract 
 
An injury to the skin alters the integrity of underlying tissues and microcirculation and thus 
certainly culminates in a wound. Wound healing is a highly complex, dynamic, interactive and 
well regulated physiological process involving blood cells, extracellular matrix, parenchyma 
cells and soluble mediators. It starts with alteration in integrity of tissues and ends with the 
formation of scar. The process of wound healing is distinguished into Haemostasis, 
Inflammation, Proliferation and Remodeling. Various cells like platelets, neutrophils, 
macrophages, lymphocytes, angiocytes, keratinocytes, fibroblasts and factors like platelet 
derived growth factor, transforming growth factor, platelet derived epidermal growth factors, 
fibroblasts growth factor, albumin, fibrinogen, fibronectin, anti hemophilic factor, pro accelerin 
etc play a significant role in wound formation and its amelioration at some crucial points for a 
brief period of time. Management of chronic wounds requires the use of antimicrobial 
application so as to eliminate the bacterial colonial biofilm formation at the injury which hinders 
the recovery. Different pathological parameter serves as biomarker for the evaluation and 
assessment of wound severity, measure to take care and the alternatives to be needed. Thus 
timely accurate and precise wound care may prevent the bio burden in the wound and the various 
sufferings to the patient. 
 
 
 
 
 
 
Introduction 
Wound healing is an extremely organized and complicated event. An injury to the skin changes 
the integrity of underlying tissues and microcirculation and thus culminates in a wound1. In order 
to replace and restore the function of damaged tissues, wound healing is required2. Wound 
healing is a highly complex, dynamic, interactive and well regulated physiological process 
involving blood cells, extracellular matrix, parenchyma cells and soluble mediators. It starts with 
alteration in integrity of tissues and ends with the formation of scar. 3 The process of wound 
healing is distinguished into the following phases. 
 
Haemostasis can be defined as spontaneous arrest of blood loss from damaged blood vessels. It is 
an essential and brief process of wound healing which not only prevents bleeding but also 
supplies active biomolecules that promotes healing4. It occurs within a few minutes of injury, 
trauma or other similar destruction to tissue results in the disruption of blood vessels.  Following 
tissue injury, the blood vessels immediately constricts around the site of injury by releasing 
vasoactive amines to reduce bleeding9.  It involves two processes, platelet aggregation and blood 
clotting8. The platelets adhere themselves to the exposed sub-endothelial of the injured vessels. 
This result in their activation and subsequent release of factors such as platelet derived growth 
factor (PDGF), transforming growth factor –β (TGF β), platelet derived epidermal growth factors 
(EGFs), fibroblasts growth factor- 2 (FGF -2), albumin, fibrinogen, fibronectin, anti-hemophilic 
factor, and pro accelerin, etc4, 9. 
Inflammation is the second phase which involves the formation of stable fibrin clot called 
Coagulation. This process involves both intrinsic and extrinsic cellular pathways. Activated 
platelets stimulate pro-coagulant enzymes to produce thrombin.  Thrombin then acts on the 
1. Haemostasis 2. Inflammtion
3. Proliferation 4. Remodelling
woundhealing
circulating fibrinogen to form a stable fibrin clot4. This fibrin clot mainly contains fibrin mesh 
aggregated platelets and certain RBCs. This clot prevents the loss of fluids and electrolytes from 
the site of injury and reduces contamination from external environment.6 Aggregated platelets 
present within the fibrin clot releases various cytokines and growth factors which directs 
subsequent events of wound healing.7 Inflammation phase is essential prerequisite for wound 
healing process. It can last up to 4 days after injury. It is characterized by redness, swelling, pain, 
warmth, and loss of function. After initial vasoconstriction, vasodilation occurs due to the release 
of endothelial products and mast cell derived factors such as histamine, prostaglandins and 
leucotrienes from damaged cells. Simultaneously the surrounding endothelial cells develop gaps 
in order to exudate plasma from intravascular space to extravascular compartment. This in turn 
leads to the generation of pain associated with edema. Inflammatory response enhances vascular 
permeability and this result in the migration of neutrophiles (PMN’s), followed by monocytes, 
lymphocytes, basophils and esinophils. Migration of neutrophils peaks within 48 hours. 
Europhiles engulfs debris and bacteria and thus provides first line of defense against 
infection when neutrophils begins to wane, monocytes migrates to the injured sites and matures 
into tissues macrophages. These are considered as the vital regulatory cells in the inflammatory 
process. They phagocytise bacteria by releasing biologically active oxygen intermediate and 
enzymatic proteins and thus provides second line defense. In addition, macrophages produce 
various chemotactic and growth factors (EGF’s, TGF β, FGF and IL 1) that effectively promote 
cell migration, proliferation and production of tissue matrix1. Lymphocytes also play an 
important role in immune response with very similar functions4. Macrophages and lymphocytes 
exist nearly for seven days and then disappear9. 
The third phase is the proliferation phase which starts after 2- 3 days of injury and continues for 
about 21 days. The events involve in this phase includes re-epithelialization which includes 
migration and proliferation of epidermal keratinocytes and re-establishment of basement 
membrane zone. The re-epithelialization can be defined as replacement of dermal as well as sub-
dermal tissues following an injury. It occurs within 24 hours of injury. Following events like 
migration and proliferation of epidermal keratinocytes are involved in re-epithelialization 
process. The initial event in re-epithelialization is migration of epidermal keratinocytes from skin 
appendages like hair follicles, sweat glands and wound edges into the wound. After 24 – 48 
hours of injury, epidermal cells at the wound margins start proliferating so as to ensure supply of 
sufficient cells to the healing monolayer. Migration of epithelial cells into the wound requires 
formation of actin filaments at the edges of their cytoplasm, development of pseudopodia like 
projections, disappearance of desmosomes which links cells together and hemi desmosomes 
which links cells to the basement membrane with associated elongation of the keratinocytes. 
Integrin receptors present on the epidermal cells helps them to interact with the extracellular 
matrix proteins like vironectin and fibronectin. These proteins assist keratinocytes to migrate 
across the wound and separate desiccated eschar and debris from viable tissues3. In the re-
establishment of basement membrane zone, the basement membrane zone which connects 
epidermis and underlying dermis layer is destroyed following an injury, then the epithelial cells 
regenerates a new basement membrane zone within 7 – 9 days of re epithelization so as to restore 
integrity and function of skin. It involves angiogenesis which is a complex process involving 
formation of new blood vessels from pre-existing vessels to ensure supply of oxygen and 
nutrients to the newly formed granulation tissues. Production of fibroblast growth factor (FGF) 
and endothelial cell derived growth factor by macrophages and endothelial cells is mainly 
responsible for induction of angiogenesis. The former directs angiogenesis during first 3 days of 
wound healing while the latter sets the stage for angiogenesis from day 4–7 (i.e during the 
formation of granulation tissue). This process stops after the wound is filled with granulation 
tissue3, 8. 
       Injury   
    Tissue destruction and hypoxia  
Release of angiogenic factors 
FGF mediated stimulation of the release of plasminogen activator and pro collagenase 
Plasminogen and plasmin interaction leads to procollagenase to active collagenase  
Local degradation of basement membrane by the above enzymes 
Migration of the activated endothelial cells to form new blood vessels at the site 
                 Figure 1: Schematic representation of the events involved in Angiogenesis.  
Granulation tissue contains numerous capillaries and a support matrix enriched with collagen 
fibroblasts, inflammatory cells, endothelial cells, pericytes and myofibroblast. Granulation tissue 
formation commences 2- 4 days after injury. Chemical mediators released from the macrophages 
during the inflammatory phase causes fibroblast to activate. This process usually occurs from the 
4th day of injury. Activated fibroblast releases proteolytic enzymes such as MMP-1, MMP-2, and 
MMP-3 to facilitate migration into the provisional matrix of the wound clot. Fibrin, 
fibrinonectin, and hyaluronic acid molecules present in the matrix contribute to the formation of 
granulation tissue by providing scaffold for migration of cells. After migrating into the wound, 
fibroblast replaces the provisional matrix with collagenous matrix releasing collagen, elastin and 
proteinoglycans. Once the large amount of collagenous matrix is formed, the production of 
collagen will come to a halt6, 8, 9,11. Wound contraction is another complex interactive process 
involving extracellular matrix and cytokines. This process commences after 4-5 days of injury 
and continues for about 2 weeks. After 4-6 days of injury, when the defect is covered with 
epithelial cells, fibroblast modifies into myofibroblasts which are characterized by the presence 
of actin rich filaments within their cytoplasm, desmsomes, hemidesmsomes, multilobular 
nucleus, and surplus rough endoplasmic reticulum. Since myofibroblasts are connected to each 
other as well as to margins of wound, they draw the edges f the wound together and thus contract 
the complete granulating bed. At the same time, collagen is released to form a rigid scaffold to 
hold wound in place.1, 3, 8, 11.  Finally the last process is called Remodeling which involves 
transition of granulation tissue to a scar. A scar is a relatively acellular and avascular mass of 
collagen which functions to restore continuity, function and strength of tissue. During this phase, 
collagen fibres are recognized into a highly organized lattice structure with more tensile strength. 
Such remodeling gradually replaces type – I collagen with type –III until normal skin ratio of 4: 
1 is reached. After 3 months, wound regains 80% of its original strength. The remodeling process 
continues upto 1 year, however there is no further increase in its tensile tissue strength.  
                                                               Table: 1 
 
Wound healing stage Major Cells involved  Days post injury 
1. Haemostasis Platelets Immediate 
Summary of all four wound healing phases. Major cells involved and days incurred 
in each phase are listed. 
2. Inflammation Neutrophils 1-4 
3. Proliferation 
   granulation contraction 
Macrophages, lymphocytes, 
angiocytes, Fibroblasts, 
keratinocytes,  
4-21 
4. Remodeling Fibroblasts 21 days – 2 years. 
 
 
Prevention and treatment of chronic wounds 
 
Chronic wound is a wound which fails to restore the anatomic and functional integrity of the 
injured site in an orderly and timely manner despite  optimum and appropriate medical care 
15,20,29
. They persist for weeks, months and even years23. The degree of wound ranges from 
superficial lesion to deep tissue destruction affecting muscles, tendons and bones30. Chronic 
wounds are common problem throughout the world and are usually seen in elderly and bed 
bound patients27. Around 3 - 6 million Americans are affected with chronic wounds with 
estimated treatment cost up to $25 billion annually29. 
Chronic wounds are characterized by prolonged inflammatory phase, no initial bleeding to 
induce production of fibrin and secretion of growth factors, altered migration of epithelial 
keratinocytes, failure or delayed re-epithelialization due to absence of required extracellular 
matrix, no decrease in wound size with time, increased levels of matrix degrading proteases, 
increased levels of matrix metalloproteases (MMP-1(collagenase), MMP-2 (Gelatinase A) and 
MMP-3 (Gelatinase B). reduce levels of protease inhibitors, reduction in surface growth factors, 
increased degradation of fibronectin, vitronectin, decreased mitotic activity, reduced  fibroblastic 
response to growth factors, enhanced proportion of senescent (unresponsive) cells restricting 
ECM production, presence of necrotic tissue in wound bed, excess exudates and slough (yellow 
fibrinous tissue containing fibrin, pus and proteinacious materials) on wound surface, poor blood 
supply, persistent pain. frequent wound breakdown, lack of healthy granulation tissue (ECM), 
Clinical /subclinical infection.15, 17, 28 
Various factors do hamper wound healing and they can be categorized into local factors such as 
poor blood supply, enhanced skin tension, wound dehiscence, inadequate venous drainage, 
presence of foreign body in the depth of wound, infection, tissue maceration, ischemia etc, 
Systemic factors such as advanced age, poor nutrition, obesity, smoking, shock, diseases 
(diabetes, hepatic and renal disease, cancer), medications (Corticosteroids, immunosuppressant, 
anticoagulants), chemotherapy and radio therapy, malacoplakia (an inflammatory condition 
caused by bacteria or fungi) etc. Improper or delayed wound healing may result in several 
complications like anaemia, contractures and deformity in nearby joints, microbial colonization, 
fistula, heterotopic calcification, malignant changes in the ulcer bed, osteomyelitis, septicemia, 
sinus formation, systemic amyloidosis and unrecognized malignancy have been reported 13b, 14.  
In the management of wounds it is better to understand types of chronic wounds / ulcers 16,26,27 
                                                 
 
 Arterial ulcer  
It is a round shaped wound caused due to inadequate blood supply to the feet or legs27.  They 
account for 10 – 20 % of all leg ulcers. Patients with arteriosclerosis are more likely to have 
arterial ulcers15. It is regarded as the first symptom of peripheral arterial occlusive disease 
(PAOD). 
1.Arterial 
ulcers
2.Venous ulcers
3.Diabetic 
ulcers
4.Pressure 
ulcers
Ulcers
Risk factors  
Diagnosis of arterial ulcers is based on the evaluation 
history, where patients with PAOD will describe nocturnal claudication and decreased ability to 
walk distances. Skin color is indicative of arterial perfusion. A pale, dry, thin hairless skin 
indicates ischemia. Skin is also evaluated for temperatu
the surrounding skin. Capillary refilling where compression of great toe between forefinger and 
thumb gives capillary refill. Capillary refill > 3 seconds indicates decreased perfusion. 
Dependant rubor (reactive hyperthermia) in which the foot becomes ruddy (dark red) when the 
affected extremity is placed below the knee level. This is known as dependent rubor. The 
presence of palpable pulses at dorsalis pedis artery and posterior tibial artery is checked. 
•Diminished 
or absent 
pulses
•Absences of 
Oedema
Pale, dry or 
shiny skin
Claudication
Advanced age
Atheroscleroosis
Diabetes
Dry black toe 
of the various aspects such as c
re changes. Ischemic tissue is cooler than 
•Paresthesia
•Soft tissue 
atropy
Hypertopic 
(thick)nails 
Absences of hair 
in case of 
chronic 
atherosclerosis
Cholesteriolemia
Hypertension
Hypothyroidism obesity
Renal failure
Smoking
Decreased 
walking ability
Arterial 
ulcers 
 
 
linical 
 
Diminished or absent pulse represents arterial insufficiency. Non-invasive as well as invasive 
arteriogram tests are performed to diagnose arterial ulcers. With the aid of droppler machine, 
arterial blood flow to the leg and arterial blood pressure of the leg is assessed. B.P of the foot is 
then compared with the B.P of the arm. This comparison gives the Ankle brachial Index (ABI), 
which indicates the extent of diminution of blood flow to the foot. An ABI < 0.4 indicates poor 
arterial blood flow to the foot. Arteriogram is employed to determine the exact location of 
arterial blockage of the leg. 
Treatment: The general principle of treatment are wound bed preparation which is an essential 
paradigm in the management of chronic wounds.  The goal is to eliminate all barriers to healing 
process so that wound repair can progress in an orderly and timely fashion. The principal 
components of wound healing forms a framework that offers practitioners a systematic approach 
to wound management. This framework has been named TIME. 
T: Tissue management 
I: Inflammation and infection control 
M: Moisture balance  
E: Epithelial management 
In tissue management chronic wounds are contaminated and colonized by bacteria, fungi and 
other pathogens. These pathogens hinder the healing process by competing for nutrients and 
oxygen present within the wound and releasing toxic metabolites. Therefore wound debridement 
is carried out. Debridement removes devitalize tissue, reduces the number of pathogens, toxins 
and substances that impairs healing process and thereby promotes buildup of healthy tissue. In 
inflammation and infection control, the infected wound is characterized by erythema, swelling, 
warmth and pain. If the wound is infected, devitalized tissue and excess exudate should be 
cleaned off and an appropriate antimicrobial agent should be applied. Antimicrobials reduce the  
infection and the associated pain. They keep the wound moist. Examples include povidone 
iodine, cadexomer iodine and honey. Cadexomer iodine is being increasingly employed as it kills 
bacteria without developing resistance and toxicity. In mild-moderate infections, oral antibiotics 
like amoxicillin, cephalexin should be given. In limb threatening infections, patients should be 
hospitalized and treated with I.V antibiotics. In Moisture Balance, wound cleansing is followed 
by application of dressings so as to remove the exudate, protect wound from contaminants and to 
keep wound moist. They are left on for prolonged periods to provide an environment conducive 
to natural healing process. Highly advanced wound dressings contain polymers that facilitate 
better absorption control and fluid management. In addition they also alleviate the risk of 
maceration at wound edges. Silver containing dressings are appropriate for heavily colonized 
wounds and for those at high risk of infection. 
 
 Table: Wound type and necessary dressing technique 
 
 
 
 
 
 
 
 
 
 
Dressing should be changed at least twice a day and with each dressing change, wound should be 
cleaned with a mild soap and saline or water. In Epithelial management, the aim is to restore the 
damaged skin and its function. Various adjuvant therapies are used such as Hyperbaric oxygen 
therapy (HOT), which is applied to accelerate the healing of non-healing wounds. It enhances 
oxygen
 
concentration in all tissues including those with diminished blood flow. It stimulates 
angiogenesis in areas with poor blood supply and thereby improves blood circulation to blocked 
arteries and compromised organs. It increases SOD levels. It assists in treating infection by 
restoring leucocytes action and enhancing their phagocytic effect. It also exhibits anti-
inflammatory and bactericidal potential. The Growth factors application factors plays a pivotal 
role in controlling all phases of wound repair. They promote growth and migration of endothelial 
cells, fibroblasts and keratinocytes into the wound bed. Chronic wounds are deficient in growth 
Wound type  Dressing technique 
Dirty /Infected wound  Wet to dry 
technique should 
be done until 
wound is cleared. 
Clean wound  Wet to wet 
ointment based 
dressing 
factors. Therefore to compensate for this deficiency and allow normal healing to progress, 
topical application of these factors is recommended. Eg: Bacaplermin. Gene therapy is being 
developed to deliver growth factors more effectively. The Stem cell therapy have proliferating 
capacity and the ability to differentiate into different cell types and form various cytokines and 
growth factors. This therapy is applied to introduce new cells into damaged tissue . Eg: 
Endothelial progenitor cells.  
The Vacuum assisted wound closure/Negative pressure wound therapy (NPWT) involves 
application of negative pressure (suction) under a bandaged, sealed tightly over the wound bed. 
The suction effect withdraws bacteria and exudates away from the wound bed, pulls the edges 
together and fills the wound with granulation tissue. Skin substitutes involve a human tissue or a 
bioengineered tissue is used to support wound closure. They are used to treat partial and full 
thickness venous ulcers of more than one month and full thickness diabetic ulcers. The 
Electrotherapy causes muscles to contract, augments muscles strength and promotes blood 
circulation to the affected area. The Ultrasound therapy degrades mast cells and causes the 
release of histamine and other mediators and thereby prolongs acute inflammatory phase. It also 
stimulates fibroblasts to secrete collagen leading to increased wound contraction and tensile 
strength. Malnutrition is directly correlated with impaired wound healing. It results in reduced 
fibroblast proliferation, cellular and humoral immunity and impairs neovascularisation. 
Prevention: Management of the underlying diseases not only helps to prevent future occurrence 
but also reduce overall mortality. Smoking cessation, management of hypertension, diabetes and 
hypercholesterolemia decreases long term ischemia and ulcer development. External pneumatic 
compression and passive warming of the extremity with a boot improves arterial flow in 
ischemic limbs and thus helps to avoid arterial ulcers. Arterial insufficiency also arises as a result 
of trauma to the legs and feet of the patients. Hence, leg and foot protection with soft, comforting 
and properly fitting shoes is the key to ulcer prevention. Foot protection is particularly important 
in patients with coexisting neuropathy. In patients with PAOD, neuropathy, toe nail trimming 
should be performed by a podiatrist. 
 
 
Venous ulcers 
Venous ulcers are irregular sores that develop when the valves of the leg veins (that prevents the 
back flow of blood) becomes damaged. As a consequence, pressure in the venous circulation 
increases and this causes the fluid to ooze out of the veins below the skin resulting in swelling, 
thickening and damaged to the skin. Damaged skin breaks open to form ulcers. They account for 
7 – 9% of the chronic wounds30. 
Signs, Symptoms and Risk factors  
 
S.No          Signs and symptoms              Risks factors 
1 Edema Deep venous thrombosis 
2 Pain  Previous vein surgery 
3 Skin discoloration  Lipodermatosclerosis 
4 Leg tiredness Lower extremities trauma 
5 Venous dermatitis Cellulitis 
6 Itching Venous hypertension 
7 Wet and weeping wounds Immobility 
8 Burning Obesity 
9 Palpable pulse Calf muscle pump dysfunction 
  
Diagnosis of venous ulcers is based on clinical histology, physical examination and lab tests. 
Clinical history involves the duration of wound, location prior treatment, history of phlebitis, 
deep venous thrombosis (DVT), Venous hypertension, factors that exacerbates wound, its 
reoccurrence pattern etc are thoroughly reviewed. Reoccurrence of ulcers in the same area is 
indicative of venous ulcers. Physical examination involves ulcer distribution which is typically 
found over malleoli, appearance of shallow irregular margin, swelling, lipodermatosclerosis, 
along with fibrosis of normal adipose tissue. The capillary refill is normally < 3 seconds and the 
surrounding skin is hyper-pigmented and oedematic. The diagnostic tests performed are Doppler 
ultrasonography, phlebography, duplex ultrasonography and venography aids to diagnose venous 
ulcers. Measurement of ABI using Doppler study rules out presence of arterial disease. 
Ultrasound based duplex is standard for the assessment of venous system. It allows 
determination of location and the extent of disease and also assists to differentiate between reflux 
and obstruction.  
Treatment includes compression/support therapy which is regarded as standard of care. Methods 
include inelastic compression, elastic compression and intermittent pneumatic compression. It 
improves venous reflex, ameliorates pain associated edema and accelerated healing process. 
Another treatment involves Leg elevation which is the elevation of the leg above the heart level 
reduces edema, improves microcirculation and increases oxygen delivery to ischemic tissues by 
pulling fluid and blood in right direction towards heart. The third treatment is the dressings 
which promote healing process and prevents adherence of bandages to wounds when used as an 
adjuvant to compression therapy. Another treatment is the negative pressure wound therapy 
which decreases the depth and volume of wound. Treatment with medications such as 
pentoxyfilline and oral zinc are given along with compression therapy to accelerate healing. 
Antimicrobials are given to control bioburden, povidone iodine, ethacridine, mupirocin etc are 
applied. In case of suspected cellulitis, antibiotics are administered orally. The hyperbaric 
oxygen therapy is used as an adjuvant therapy due to its antibacterial and anti-inflammatory 
potential. Also Debridement is done of the Necrotic or devitalized tissues by removing them by 
sharp mechanical or autolytic means. Skin grafting is done in the case of refractory venous ulcers 
Prevention of venous ulcers should focus on the management of its risk factors. Continual use of 
compression stockings by individuals with venous hypertension and or phlebitis helps prevents 
formation of venous ulcers. Calf muscles exercised have been shown to improve calf function 
and this can help avoid ulcer occurrence. Prophylactic therapy in patients with deep vein 
thrombosis prevents reoccurrences of disease. SEPS (sub facial endoscopic perforator surgery) is 
the method of choice for decreasing ambulatory venous pressure in the leg. Treatment with 
suitable systemic antibiotics in case of cellulitis helps prevent infection.Venous surgery, if 
performed with compression therapy helps to prevent occurrence of venous ulcers. 
 
 
 
 
Diabetic Ulcers 
It is a wound or sore commonly found on the foot, heals or toes of diabetics. Diabetics with 
ulcers are at a greater risk (15 %) for amputation. Diabetes causes neuropathy which in turn 
causes loss of protective sensation and coordination of muscles in legs and feet. It is the leading 
cause for most foot and leg amputations. The signs and symptoms are high blood glucose levels, 
infections, swelling, erythema, pus generation, fever etc. The risk factors involves diabetic 
neuropathy, structural foot deformity, ulceration, infection, callus thick toe nail, obesity, 
smoking, retinopathy, peripheral arterial occlusive disease, poor glycaemic control, advanced 
age, alcohol. The clinical history of previous trauma, neuropathy, revascularization and ulcers 
are vital informative pieces in developing wound care plan. The inspection involves meticulous 
examination of patient’s skin covering top, sole and sides of both feet, areas between toes and 
back of the heels for the signs of edema and cellulitis. Hard, callused and ruddy skin is indicative 
of high pressure and worsening infection. The vascular assessment involves palpitation of both 
the dorsalis pedis and posterior tibialis artery. Diminished pulses illustrate ischemia. If pulses are 
non-palpable, ABI is performed to quantify the information. Transcutaneous oxygen 
measurement serves as an alternative to ABI. Hematological assessment is done in diabetic 
patients by complete blood cell count, serum creatinine and plasma hemoglobin should be 
monitored. The latter parameter is standard for long term monitoring of blood glucose level. 
Increased HbA1C is suggestive of coronary heart diseases, neuropathy, nephropathy and 
retinopathy. In neurological assessment, Semmes – Weinstein monofilaments (log) have been 
used to assess protective sensation. Inability to sense the presence of monofilament on wound 
signifies neuropathy which may render a patient susceptible to foot ulceration. 
The principal components of diabetic ulcer treatment includes Off loading which is the primary 
component in treatment of diabetic ulcers. Crutches, walkers, wheel chairs are acceptable 
methods to halt weight bearing on affected foot , total contact protective caste, custom shoes 
standard shoes are also used. Another therapy called Wound therapy involves adjuvant therapy 
like NPWT (Negative pressure wound therapy) and HOT (Hyperbaric oxygen therapy) which are 
opted when wound fails to heal with above measures. 
 
Prevention includes meticulous attention to foot care and appropriate management of minor 
injuries to foot is the key to ulcer prevention and subsequent amputation. Foot care involves 
regular washing of the feet with mild soap and luke warm water followed by topical application 
of moisturizer helps maintain healthy skin. Regular trimming of toe nails and use of protective 
and properly fitting shoes reduces the incidence of ulcers. Proper foot care is the mainstay of 
prevention and is recommended in patients with history of amputation, ulcer neuropathy and 
ulcerative callus. Also 60 % reoccurrence risk in patients with healed ulcers has been reported. 
Therefore it is highly recommended to educate patients at risk of ulceration on daily foot care 
and signs of infection. Diabetic patients should have annual foot inspection for sores, cuts, 
bruises, arterial insufficiency, and loss of pain sensation, fungal toe nails and callus formation. 
Increased pressure on the foot of diabetics leads to callus formation which eventually results in 
foot ulcers. Removal of callus reduces the incidence of ulceration. Ceasing smoking and 
decreasing alcohol consumption also reduces incidence and reoccurrence of ulcers. 
 
Pressure ulcers / Bed sores 
Pressure ulcers are caused due to ischemia which occurs when pressure on the tissue is 
more than pressure in capillaries, thereby restricting blood supply to an area of skin and 
eventually resulting in bed sores. Ankles, heels, knees, elbow, shoulder blades and sacral regions 
are highly susceptible to pressure ulcers. They usually occur in unconscious, fatigue, cadaverous, 
paralyzed or bed ridden patients. Approximately 3 million Americans are affected with pressure 
ulcers. European pressure ulcer advisory panel (EPUAP) has defined pressure ulcer in 4 stages 
which are outlined below. Stage 1 involves intact skin with erythema over a bony prominence. 
The affected area is firm, soft and painful to touch. Stage 2 involves open wound in which 
epidermis and a portion of underlying dermis is lost. Appears as a shallow abrasion or blister, 
surrounding area is pinkish to red. Slough is absent. The Stage 3 is deep wound where Epidermis 
and dermis are fully lost. Subcutaneous fat is exposed. It appears as a crater and slough is 
present. In Stage 4 extensive damage occurs. Muscles, bones and tendons are visible. Slough is 
present.  
Treatment involves pressure removal from the site of ulceration which accelerates the healing 
process. Basically there are two types of pressure relieving devices, static and dynamic devices. 
Static devices include foam, gel, and air mattresses. Dynamic devices are beneficial in patients 
who cannot reposition independently and in slowly healing wounds. Example includes low air 
loss beds and air fluidized beds. Other aids include chair cushions, wedge pillows etc. Friction 
and shear reduction is done through repeated turning and repositioning helps to reduce friction 
and shear. Elevation and maintenance of the head of bed at 30° reduces shear and prevents 
complications like CHF. The wound therapy is done through surgical care. It is required only 
when wounds fail to heal despite optimum and appropriate medical care. Wound closure by 
surgical approach includes direct closure, skin grafts and musculo- cutaneous flaps. 
Prevention of pressure ulcers involves Pressure ulcer risk screening. The risk factors are best 
identified immediately after a patient is admitted to the health care setting by health care 
professionals or trained nurses. Braden scale is most widely used tool to predict development of 
pressure ulcers. It consists of six parameters namely sensory perception, activity, skin moisture, 
mobility, nutrition and friction and shear. Each parameter is assigned a score ranging from 1-4. 
Summing up of all risks gives overall risk ranging from 6 – 23. Lower the score greater is the 
risk potential.  
a. Table : Braden scale 
S.No Score Risk 
1 15 – 18 Mild 
2 13 – 14 Moderate 
3 10 – 12 High 
4 ≤ 9 Very 
high 
 
The Norton scale is a tool that assesses five risk areas for development of pressure ulcers. 
Areas include physical state, mental state, activity, incontinence and mobility. Each risk 
area is assigned a score varying from 1 – 4. Sum of all scores yields total score ranging 
from 5 - 20. 
i. Table : Norton scale 
S. No Score Risk  
1 14 Mild  
2 13 Moderate 
3 12 High  
 
Pressure Ulcer risk assessment involves assessment of physical appearance, history of previous 
ulcers, onset and duration of ulcers, factors that accelerates / impede healing, behavioral and 
cognitive status, nutritional status, use of tobacco and alcohol immobility and incontinence, 
location, size and stage of each ulcer, presence of exudates, odor, eschar, infection and wound 
margin, nutritional evaluation (Nutritional evaluation is an integral part of general screening of 
patients with pressure ulcers. In malnourished patients, adequate intake of nutrients is 
recommended), preventive interventions, pressure relief to preserve microcirculation is the key 
to ulcer prevention., to minimize shear, head of the bed is elevated and maintained upto 30°. This 
intervention also reduces complications like aspiration and CHF. 
 
Biofilms  
 
 A Biofilm can be defined as a structured community of microbial cells, adherent to living or 
inert surfaces by a self produced complex matrix of extracellular polymeric substances1. It is 
characterized by complex community interactions, extracellular matrix of polymeric substances, 
genetic diversity and structural heterogeneity. The thickness of a biofilm ranges from a single 
cell layer to 6-8cm. On an average, each biofilm is about 100µm in thickness. Slippery layer 
inside the sewage pipes, slimy green stuff surrounding a pebble in a pound dental plaque, outer 
layer of chronic wounds are a few examples of biofilms. Biofilms are the common mode of 
microbial growth that occurs in various forms in natural, industrial and hospital settings. They 
are commonly seen in hoses,  plants, ponds, rocks in water, soil particles, plastic and metal items, 
kitchen counters, walls of hot tub, swimming pools, medical implants  like ocular lenses, 
intrauterine devices, I.V catheters, heart valves, vascular grafts, reverse osmosis membrane 
filters and medical apparatuses like dialysis units, water filter systems, storage vessels, gas tubes, 
ventilator pipes etc. A biofilm consists of a sessile mushroom shaped microbial colonies of 
which each colony consists of small groups of different species of bacteria and the other 
pathogens. Extracellular polymeric matrix which protects the microbes from external 
environment and strengthens attachments of microbes to a hospitable surface.  Fluid (water) 
channels helps to supply nutrients and water to each of the bacterial and living cell. They also 
facilitate the disposal of bacterial metabolites. Communication system (quorum sensing system) 
which helps bacterial cell to communicate with other cells usually through biochemical signals in 
the community.  
 A biofilm is formed when free floating  and individual cell bacteria adhere to wet or moist 
surfaces such as foam filters, medical implants, human skin or any other hospitable surface and 
become sessile by producing a protective, slimy glue like substance.  It can be formed from a 
single bacterial species but  more commonly, it is formed by multiple species of bacteria as well 
as algae, fungi, protozoa and yeasts.  Formation of a biofilm involves three stages, attachment or 
adhesion, growth and development and dispersal or detachment. A biofilm commences to form 
when freely moving mobile bacterial cells identifies and adheres to a hospitable surface.3 This 
process is known as Twitching. Attraction towards such a surface is brought about by various 
modes like Brownian motion, chemo attraction, gravity and surfaces charge2. Attachment of 
bacterial cells to the surface depends upon the amount and type of cells present at a specific time, 
amount of nutrients available at the surface, temperature and pH, flow rate of the fluid or water. 
Initially, they adhere to the surface through weak vanderwaals forces and once they stick, they 
start producing slimy glue like extracellular polymeric substances (EPS) also called as 
Glycocalyx. EPS is made up of complex combination of DNA, glycoproteins, polysaccharides, 
lipids and proteins.  
During growth and development stage, a biofilm grows through the cell division of attached 
bacteria and changes its size and shape. As the bacterial cells within the microcolony divide, a 
critical population density known as quorum is reached32,33,34. The bacteria in the quorum 
produces signalling molecules which diffuse across the cell membranes and interact with DNA 
receptors, thus altering the phenotype of bacteria35. This process of transmittance of signals from 
cell to cell is known as quorum sensing. Consequently the microcolony further grows and 
develops into a mature polymicrobial biofilm . A mature biofilm comprises of three regions, the 
lower region mainly comprises of metabolically dormant inactive cells which are capable of 
persisting even in the most hostile environment. Removal of these cells is necessary to prevent 
their regeneration. The mid region consists of cells that regulate DNA systems, which facilitate 
horizontal gene transfer and genetic diversity within the biofilm and the top most region contains 
metabolically active cells which disperse to new locations to exert their toxicity32. Once the 
biofilm is established, fragments are programmatically released from the biofilm into the 
environment to spread and colonize new surfaces. Enzymes such as deoxyribonucleases and 
dispersin B were found to play a role in dispersal of biofilms. 
 
 
 
                       Figure 1 – BIOFILM FORMATION 
 
Biofilms increases the resistances of pathogens against antimicrobial agents, high temperature 
and host immune responses. They provide easy access to water and food. They facilitate 
exchange of metabolite and nutrient and even genetic material among organism of same and 
different species. They are useful in sewage treatment wherein they breakdown harmful 
compounds and thereby purifies water.  They are used in treating petroleum contaminated water 
of marine systems (pseudomonas putida) and nitrification. They protect the soil and water by 
forming the barriers. 
 Biofilms damage the surfaces on which they grow. This type of damage caused by them is called 
Bio-fouling. Biofilms growing on the surfaces of teeth can cause tooth decay and gum disease. 
They cause clogging and corrosion of sewage pipes. They decrease the productivity of 
equipments and they corrode the metal surfaces. They decrease the heat transfer in cooling and 
heating water systems. They also contaminate the products and make sanitation difficult in 
manufacturing areas. They cause biofouling of computer chips and marine vessels. They 
contribute to a number of health problems like atherosclerosis, chronic sinusitis, gingivitis, 
chronic wounds, cystic fibrosis, leptospirosis, osteomyelitis, otitis media, tooth decay, 
urolithiasis, urinary tract infections, and heart valve infections. 
 
A wounded tissue serves as a unique microbial niche. A wide variety of microorganisms are 
known to infiltrate a wounded tissue and interfere with the healing process9. Anaerobes, yeasts 
and filamentous fungi are recognized as potential wound pathogens. Biofilms have been 
implicated in less than 10% of acute wounds and in more than 70% of chronic wounds. They 
have been reported to be associated with a number of chronic infections ranging from dental 
plaque to prostatitis36.  
 
 
  
Figure 2 – COMMON SITES OF BIOFILM INFECTION 
 
In acute wounds, bacteria are easily identified and destroyed by the host defense systems11. 
Chronic wounds are associated with compromised hosts that demonstrate an impaired 
inflammatory phase. Inability of the immune system to destroy bacteria effectively results in the 
establishment of a biofilm which helps to overcome host’s natural defenses and other 
environmental stresses. This in turn results in prolonged inflammatory phase and subsequent 
release of free oxygen radicals and various proteases in large amounts. In the normal wound 
healing process, proteases break down the damaged extracellular matrix proteins and thus 
facilitate their removal so that a new tissue is formed and the wound heals in an orderly manner. 
But due to the excessive release of proteases, the newly formed ECM and other essential proteins 
and immune cells also get degraded. As a result, healing is impaired due to the unusual 
prolongation of the inflammatory phase that prevents wound from entering into proliferative 
phase of healing. 
 
          
             Figure 3 – BIOFILM PREVENTING HEALING PROCESS      
The microbial community living within a biofilm is known to possess properties greater than 
sum of its constituent members31. Bacteria present in biofilms are 1000 times more resistant to 
the effect of anti-microbial agents. EPS plays a pivotal role in making the biofilms resistant 
against antimicrobial therapies, host immune responses, drying, over-hydration and other 
environmental stresses. It prevents phagocytosis of the resident microbiota and allows them to 
persists for a longer period of time by one of the following mechanisms such as reduced 
permeability or uptake of antibiotic into the biofilm, diminished metabolic activity of resident 
bacteria, altered gene expression, altered microenvironment within the biofilm and increased 
production of protective enzymes via quorum sensing37. As conventional antimicrobial killing 
methods are ineffective in case of biofilm microbes, which causes an immense damage to 
equipment, drugs, man power and to life there is a need of development of strategies and devices 
to interrupt with the biofilm formation and control their growth.  
 
Biomarkers 
 
 In the year 2001, National institute of health (NIH) appointed biomarkers definitions working 
group (BDWG) to define biomarkers and related terms. BDWG has defined biomarker as “ 
characteristics that can be objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, pharmacologic responses to a therapeutic 
intervention”39,40. The term biomarker has been used in a broad sense to measure biochemical 
components in tissue and fluids and as well as imaging, chemical and physiological measures. It 
includes tools and technologies which assist in comprehending cause, diagnosis, progression, 
regression or outcome of treatment39.  It can also be described as anything which can be 
employed as an indicator of particular disease. It can be enzymes, genes, gene products, 
hormones, specific cell or molecules. Specific changes in biological structure also serve as 
biomarkers. Example blood pressure is a biomarker of stroke, C-reactive protein(CRP) is a 
biomarker of inflammation and the body temperature is a biomarker of hyperthermia. In 
molecular terms, biomarker is a subset of markers found using imaging, genomics or proteomic 
technologies3. They are produced by the diseased organ or by the body in response to disease42.  
An ideal biomarker should be safe and easy to assess. It should provide rapid, reliable and robust 
measure. It should be specific for the biological process/organ. It should be consistent across 
ethnic groups and genders. It should be analytically stable. It should be quantifiable in a readily 
obtainable sample. Cost of follow up test should be low. There should be an established 
treatment to alter the biomarker. There should be little or no overlap in biomarker levels in 
treated and untreated patients. Their levels should not vary widely in general population (i. e 
between patients). Levels should correlate with the total disease burden but they should be 
influenced by unrelated conditions and associated co-morbidities. Levels should alter quickly in 
response to specific treatments. Levels should correlate closely with all effects of therapy 43. 
Biomarkers are classified into Type-0/Natural history markers which measure the natural history 
of a disease and correlates longitudinally with known clinical indicators. The Type-1/drug 
activity markers indicate intervention and downstream effects of a drug. Type-2/surrogate 
markers are regarded as surrogate end point because a change in these markers indicates 
therapeutic effect. According to USFDA, a surrogate marker is “a laboratory measurement or 
physical sign that is used in therapeutic trials as a substitute for a clinically meaningful end point 
that is a direct measure of how a patient feels, functions, or survives and is expected to predict 
the effect of the therapy44.  According to BDWG, a clinical end point is an “a characteristic or 
variable that reflects how a patient feels or functions or how long a patient survives”. A surrogate 
end point is “a biomarker intended to substitute for a clinical end point”. 
The characteristics related biomarkers are Imaging biomarkers and Molecular biomarkers. The 
Imaging biomarkers are quantifiable characteristics which make use of various technologies to 
visualize anatomical and physiological changes occurring in the body. X-ray, computed 
tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), 
single photon emission computed tomography (SPECT) is widely used imaging techniques. In 
clinical settings, MRI is most commonly use. It is a promising biomarker in rheumatoid arthritis. 
It detects cartilage erosion and soft tissue inflammation. PET plays a pivotal role in determining 
concentration of drug in target organs and tracking how and where drugs bind to target which 
might act as a biomarker. It is also useful in visualizing targets like amyloid plaque which are 
believed to trigger Alzheimer disease. CT is currently employed in all stages of cancer 
management including early detection, diagnosis of suspected lesions and determination of 
clinical benefit3. They have many advantages like they are non-invasive, yields quantitative as 
well as qualitative information. They are highly sensitive, accelerates drug development process, 
reduces time and cost involved in drug development process. They assist in selecting proper 
candidates for treatment,  allows serial data collection, reduces inter patient variability and 
provides complete drug profile (pharmacologic effects, side effects, drug interactions) 
Molecular biomarkers are characteristic biomolecules which can be detected and quantified in 
body parts, fluids like tissue, blood. They can be genes mutations associated with acute myeloid 
leukemia, special type of cells like CD4 cells in HIV or molecules. They possess biophysical 
properties which facilitate their measurements in clinical samples, they help identify individuals 
at disease risk, aids in monitoring disease progression and predicts disease reoccurrence and 
possible therapeutic benefit. Eg: p16 is a putative molecular biomarker of cervical 
adenocarcinoma. 
The second category of biomarkers is the disease related biomarkers which includes 
diagnostic/screening biomarkers, prognostic biomarker and the predictive/stratification 
biomarkers. The diagnostic biomarkers are promising tools for early detection of diseases. These 
biomarkers are used to confirm diagnosis of a disease. They furnish the means to define a 
population with specific disease. Certain diseases are free of initial symptoms (Alzheimers 
disease and Rheumatoid arthritis). In such cases diagnostic biomarkers are helpful in predicting 
the presence of a disease at an early phase. 
 
Biomarker  Disease  
TNF-α and IL-6 Rheumatoid  
BRCA 1 and 2 Breast and ovarian cancer 
Saliva and gingival crevicular fluid (GCF) Periodontal disease 
α- fetoprotein Neural tube defects(downs syndrome) 
 
The prognostic biomarker predict possible course of the disease and responses to specific therapy 
in patients receiving standard therapy or no treatment. They also envisage disease reoccurrence 
and associate this risk with duration of progression-free survival. They form the basis for 
defining patient population for clinical trials. They identify patients for clinical trials. They 
identify patients who have poor prognosis on standard chemotherapy and who have good 
prognosis on standard treatment and who do not require intensive regimen. 
 
Biomarker  Disease  
C-erbB-2 Breast cancer 
HbA1c Diabetes 
Lactate dehydrogenase Advanced metastatic melanoma 
Procalcitonin Sepsis 
  
 
 
The predictive/ stratification biomarkers define subpopulation of patients who are likely to 
respond better to a particular treatment or most at risk of adverse effects. In brief they are 
predictors of efficacy/ toxicity of a drug .They save patient from unnecessary toxicity and 
increase their chance of receiving most suitable treatment. They improve success rate of drug 
development. They reduce medical cost. They help choose a therapy with the highest probability 
of being effective in a particular patient. 
 
 
 
 
 
 
 
The third category of biomarkers are the Exposure assessment related biomarkers45,46. They 
include biomarkers of susceptibility, biomarkers of exposure and biomarkers of effect. The 
biomarkers of susceptibility are indicators of natural or acquired ability of an individual to 
respond to the effects of exposure to a particular xenobiotic. In other words, they help to 
understand degree of response to exposure shown in individuals. They help identify susceptible 
individuals and critical times when exposure becomes most harmful. The biomarkers of exposure 
are unaltered parent chemicals or their metabolites or a product of their interaction with the 
target which can be measured within the body. They are employed to support and determine the 
exposure of individual to a specific substance providing a correlation between external exposure 
and internal dosimetry. They enable timely prevention of exposure associated damage. The 
biomarkers of effect are quantifiable biochemical, behavioral, physiological or other changes 
TIMP-4 and CD63 Astocytoma 
Biomarker  Disease  
HER-2 Predicts response to herceptin treatment against breast cancer 
KRAS Predicts resistance to EGFr antibody therapy against metastatic 
colorectal cancer 
C-KIT Indicator of response to gastrointestinal stromal tumor(GIST) 
within an individual indicating exposure to a compound and possible health impairment .They 
are used to document adverse effects elicited by external exposure and absorbance of a chemical. 
Thus the correlation of biomarker between exposure and effect contributes to dose-response 
relationship. 
At present, there are no effective diagnostic tools to determine the biological activities occurring 
within the wound 40. Three types of tests are commonly employed in the management of wound. 
Nonspecific tests are employed to provide data specific to the patient and clinical context. 
Example: ESR values47. Diagnostic tests are employed in predicting and managing wound 
outcomes, assessing the cause of a wound and its healing status, identifying complications which 
delay wound healing and to develop effective wound management plans using established wound 
protocols2. Example: wound tissue culture and sensitivity values. Theranostic tests are employed 
to indicate the necessity for a particular therapy and the form of treatment that must be chosen 
for a specific condition. Example: selection of monoclonal antibody trastuzumab to treat breast 
cancer 47. 
Biomarkers are currently being investigated for use as either diagnostic tool or therapy for 
treating chronic wounds45. Nitric oxide and proteases are promising biomarkers that play a 
critical role in wound repair 40,47,48. L-arginine in wounds get metabolized by three isoforms of 
nitric oxide synthase (NOS) to citrulline and nitric oxide. All these NOS isoforms are present in 
the skin and are produce during wound healing process by inflammatory cells47,49 . 
Environmental as well as biological factors influence wound healing process and NO is one such 
factor which regulates wound inflammation, angiogenesis, collagen deposition, epidermal cell 
migration, and wound tensile strength40. It serves as an antimicrobial, vasodilator, antiplatelet 
aggregator and promoter of vascular permeability and thereby plays a pivotal role in 
inflammatory phase. It hastens angiogenesis by stimulating factors which in turn induces 
endothelial cell migration, adhesion and eNOS expression. It indirectly promotes re-
epitheliazation by acting as a chemo-attractant of IL-1 which is an efficient modulator of 
keratinocyte proliferation, recruitment and differentiation. It enhances production of collagen in 
wound derived as well as skin derived fibroblasts and also assists in fibroblasts activation by 
transferring an inactive TGF-β1 to an active form49. Generation of nitric oxide is known to 
increase in wounded tissue due to activation of cNOS and increased production of iNOS50. 
Consequently, the bioactivity of NO also increases. NO gets metabolized to nitrate (NO3-) and 
nitrite (NO2-) which are together termed as NOx. These metabolites are present within the 
plasma, urine and tissue . Wound fluid NOx is immensely employed as a surrogate marker for 
wound NO bioactivity48. Determination of NO bioactivity of wound aids to predict wound 
outcomes for chronic wounds, regulate the effectiveness of chosen treatments, and generate 
unconventional dressings or treatment on the basis of their ability to improve NO bioactivity of 
wound 2. Matrix metalloproteinases (MMPs) and human neutrophil elastase (HNE) are one of the 
major proteases involved in the wound healing process48. They are essential factors for all phases 
of wound healing. They annihilate degraded protein, assists migration to center of the wound, 
damage the ECM, remodel the granulation tissue , regulate tissue angiogenesis and activity of 
growth factors (GFs). During normal wound repair , protease levels initially increases and then 
falls to very low levels by one week whereas in case of chronic wounds, protease activity 
becomes too high as a result of which ECM and newly formed tissue gets damaged and the 
healing process gets impaired. Thus high protease activity is a promising biomarker to predict 
impaired healing of both acute and chronic wounds48. Novel thera[pies are needed to initiate 
effective wound repair process, one such therapy is 3M TM Tegaderm TM matrix which helps to 
diminish total MMP production and thereby helps hastens wound healing49. Reduction in wound 
area by 2-4 weeks is another indicator of the ability of wound to heal by 3 months. For diabetic 
foot ulcers, 50% reduction in wound area by week 4 is predictive of good wound healing 
whereas for venous leg ulcers, a reduction of 20- 40 % within 2-4 weeks is predictive of healing. 
Wounds that fail to show these levels of healing within these times need to be re-assess and re-
evaluated for the care regimen48. 
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